Tags

Type your tag names separated by a space and hit enter

Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.

Abstract

This study examined the association between symptomatic benign prostatic hyperplasia (BPH) and prostate cancer risk in 5,068 placebo-arm participants enrolled in the Prostate Cancer Prevention Trial (1993-2003). These data include 1,225 men whose cancer was detected during the 7-year trial--556 detected for cause (following abnormal prostate-specific antigen or digital rectal examination) and 669 detected not for cause (without indication), as well as 3,843 men who had biopsy-proven absence of prostate cancer at the trial end. Symptomatic BPH was assessed hierarchically as self-report of surgical or medical treatment, moderately severe symptoms (International Prostate Symptom Score >14), or physician diagnosis, and analyses were completed by BPH status at baseline (prevalent) or BPH prior to cancer diagnosis or study end (prevalent plus incident). Controlled for age, race, and body mass index, neither prevalent (risk ratio = 1.03, 95% confidence interval: 0.92, 1.14) nor prevalent plus incident (risk ratio = 0.96, 95% confidence interval: 0.87, 1.06) symptomatic BPH was associated with prostate cancer risk. This lack of association was consistent across subgroups defined by type of BPH-defining event (treatment, symptoms, or physician diagnosis), prompt for prostate cancer diagnosis, and prostate cancer grade. This study provides the strongest evidence to date that BPH does not increase the risk of prostate cancer.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA. jschenk@fhcrc.org

    , , , , , ,

    Source

    American journal of epidemiology 173:12 2011 Jun 15 pg 1419-28

    MeSH

    5-alpha Reductase Inhibitors
    Aged
    Aged, 80 and over
    Case-Control Studies
    Finasteride
    Humans
    Male
    Middle Aged
    Prevalence
    Prostatic Hyperplasia
    Prostatic Neoplasms
    Risk Factors

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial
    Research Support, N.I.H., Extramural

    Language

    eng

    PubMed ID

    21540324

    Citation

    Schenk, Jeannette M., et al. "Association of Symptomatic Benign Prostatic Hyperplasia and Prostate Cancer: Results From the Prostate Cancer Prevention Trial." American Journal of Epidemiology, vol. 173, no. 12, 2011, pp. 1419-28.
    Schenk JM, Kristal AR, Arnold KB, et al. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol. 2011;173(12):1419-28.
    Schenk, J. M., Kristal, A. R., Arnold, K. B., Tangen, C. M., Neuhouser, M. L., Lin, D. W., ... Thompson, I. M. (2011). Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. American Journal of Epidemiology, 173(12), pp. 1419-28. doi:10.1093/aje/kwq493.
    Schenk JM, et al. Association of Symptomatic Benign Prostatic Hyperplasia and Prostate Cancer: Results From the Prostate Cancer Prevention Trial. Am J Epidemiol. 2011 Jun 15;173(12):1419-28. PubMed PMID: 21540324.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. AU - Schenk,Jeannette M, AU - Kristal,Alan R, AU - Arnold,Kathryn B, AU - Tangen,Catherine M, AU - Neuhouser,Marian L, AU - Lin,Daniel W, AU - White,Emily, AU - Thompson,Ian M, Y1 - 2011/05/03/ PY - 2011/5/5/entrez PY - 2011/5/5/pubmed PY - 2011/9/23/medline SP - 1419 EP - 28 JF - American journal of epidemiology JO - Am. J. Epidemiol. VL - 173 IS - 12 N2 - This study examined the association between symptomatic benign prostatic hyperplasia (BPH) and prostate cancer risk in 5,068 placebo-arm participants enrolled in the Prostate Cancer Prevention Trial (1993-2003). These data include 1,225 men whose cancer was detected during the 7-year trial--556 detected for cause (following abnormal prostate-specific antigen or digital rectal examination) and 669 detected not for cause (without indication), as well as 3,843 men who had biopsy-proven absence of prostate cancer at the trial end. Symptomatic BPH was assessed hierarchically as self-report of surgical or medical treatment, moderately severe symptoms (International Prostate Symptom Score >14), or physician diagnosis, and analyses were completed by BPH status at baseline (prevalent) or BPH prior to cancer diagnosis or study end (prevalent plus incident). Controlled for age, race, and body mass index, neither prevalent (risk ratio = 1.03, 95% confidence interval: 0.92, 1.14) nor prevalent plus incident (risk ratio = 0.96, 95% confidence interval: 0.87, 1.06) symptomatic BPH was associated with prostate cancer risk. This lack of association was consistent across subgroups defined by type of BPH-defining event (treatment, symptoms, or physician diagnosis), prompt for prostate cancer diagnosis, and prostate cancer grade. This study provides the strongest evidence to date that BPH does not increase the risk of prostate cancer. SN - 1476-6256 UR - https://www.unboundmedicine.com/medline/citation/21540324/Association_of_symptomatic_benign_prostatic_hyperplasia_and_prostate_cancer:_results_from_the_prostate_cancer_prevention_trial_ L2 - https://academic.oup.com/aje/article-lookup/doi/10.1093/aje/kwq493 DB - PRIME DP - Unbound Medicine ER -